Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Genitourinary 2Dermatologic 2Thoracic 1Plasma cell 1Myeloid 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × keyhole-limpet hemocyanin × Genitourinary × Clear all
NCT00006034 2013-05-15

Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Genitourinary

Urinary Bladder Neoplasms

NCT00003819 2013-03-19

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
21 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡